Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
January 29, 2001
- NHI Program Suffers from Ordinary Loss of \119 Bil. in 1999
January 29, 2001
- Tsuruha: Full-year Sales to Total \80.9 Bil.
January 29, 2001
- Fujirebio: Net Loss due to New Retirement Allowance Accounting
January 29, 2001
- Meiji Seika to Strengthen Its Overseas Business Structures: Vice President Ogawa
January 29, 2001
- PAJ President Uehara Stresses Importance of Self-medication
January 29, 2001
- National Burden Rate Can Be Reduced 10% Through Reform: Koseisho Study Team
January 29, 2001
- Council to Study Ways to Supply Drug Information to Public
January 29, 2001
- Jovi to Increase Its Member Stores to 3,000
January 29, 2001
- REGULATORY NEWS IN BRIEF
January 29, 2001
- JIRA Aims at Introducing Medical Devices Law
January 29, 2001
- Clinical Trial Support System Established in 5 Nat'l Univ.
January 29, 2001
- Olympus Aims at \100 Bil. Sales with Genomic Healthcare
January 29, 2001
- In vitro Fertilization Using Sperm, Ova from Third Parties to Be Approved
January 29, 2001
- Economy, Trade, Industry Ministry to Help Handicapped Persons Obtain Access to Internet
January 29, 2001
- Government to Refuse Disclosure of AIDS Study Group's Minutes
January 29, 2001
- NPO to Hold Fair to Help Elderly Participate in Social Activities
January 29, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 29, 2001
- Aiming at \100 Billion Sales in 2005: Mr Ogawa of Nippon Roche
January 29, 2001
- Most Patients Satisfied with Administration Method for Zithromac
January 29, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…